- Active not recruitingPHASE3
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
This study is looking at a new combination of medicines, naporafenib and trametinib, for people with a specific type of advanced melanoma. It aims to see if this combination works better than standard treatments for patients whose melanoma has certain genetic changes and has progressed after other treatments.
For: Advanced or Metastatic NRAS-mutant MelanomaUnited States · Australia · Canada - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) when used with chemotherapy for newly diagnosed, advanced Hodgkin lymphoma. It aims to see which combination works best at shrinking the cancer and keeping it away.
For: Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Ann Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaUnited States · Canada · Puerto Rico - Active not recruitingPHASE2
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
This study is testing a new combination treatment for advanced soft tissue sarcoma. It combines a drug called onfekafusp alfa with dacarbazine. Researchers want to see if this combination is safe and effective for people who have already had other treatments.
For: Soft Tissue SarcomaFrance · Germany · Italy - RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France - RecruitingPHASE3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.
For: Alveolar Soft Part Sarcoma · Leiomyosarcoma · Synovial SarcomaUnited States · China · Italy - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
For: Hodgkin LymphomaUnited States · Canada - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia